Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists

European Journal of Medicinal Chemistry

Volumn 56, Issue , 2012, Pages 127-133

  Su, Jung Chen ^a   Chen, Kuen Feng ^b   Chen, Wei Lin ^a   Liu, Chun Yu ^a,c   Huang, Jui Wen ^e   Tai, Wei Tien ^b,d   Chen, Pei Jer ^b,d   Kim, Inki ^f   Shiau, Chung Wai ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^f Asan Medical Center   (South Korea)

Author keywords

Cytotoxicity; Obatoclax; SHP 1; STAT3

Indexed keywords

2 [2 [(1H PYRROL 2 YL)METHYLENE] 3 METHOXY 2H PYRROL 5 YL] 1H INDOL; 2 [2 [(1H PYRROL 2 YL)METHYLENE] 3 METHOXY 2H PYRROL 5 YL] 5 BROMO 1H INDOL; 2,4 THIAZOLIDINEDIONE; ANTINEOPLASTIC AGENT; FURAN; INDOLE; OBATOCLAX; OBATOCLAX DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE SHP 1; PYRROLE; STAT3 PROTEIN; THIOPHENE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA;

EID: 84984568875     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.08.024     Document Type: Article

References (18)

1. L.R. Roberts Sorafenib in liver cancer-just the beginning N. Engl. J. Med. 359 2008 420 422
2. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, and J. Bruix Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390
3. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, R.A. Smith, B. Schwartz, R. Simantov, and S. Kelley Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discov. 5 2006 835 844
4. M.H. Kang, and C.P. Reynolds Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 15 2009 1126 1132
5. L.M. Witters, A. Witkoski, M.D. Planas-Silva, M. Berger, J. Viallet, and A. Lipton Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor Oncol. Rep. 17 2007 465 469
6. A.P. Martin, C. Mitchell, M. Rahmani, K.P. Nephew, S. Grant, and P. Dent Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy Cancer Biol. Ther. 8 2009 2084 2096
7. P. Perez-Galan, G. Roue, M. Lopez-Guerra, M. Nguyen, N. Villamor, E. Montserrat, G.C. Shore, E. Campo, and D. Colomer BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells Leukemia 22 2008 1712 1720
8. A. Jona, N. Khaskhely, D. Buglio, J.A. Shafer, E. Derenzini, C.M. Bollard, L.J. Medeiros, A. Illes, Y. Ji, and A. Younes The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors Exp. Hematol. 39 2011 1007 1017
9. J. Li, J. Viallet, and E.B. Haura A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells Cancer Chemother. Pharmacol. 61 2008 525 534
10. P.K. Paik, C.M. Rudin, A. Brown, N.A. Rizvi, N. Takebe, W. Travis, L. James, M.S. Ginsberg, R. Juergens, S. Markus, L. Tyson, S. Subzwari, M.G. Kris, and L.M. Krug A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies Cancer Chemother. Pharmacol. 66 2010 1079 1085
11. G. Tang, C.Y. Yang, Z. Nikolovska-Coleska, J. Guo, S. Qiu, R. Wang, W. Gao, G. Wang, J. Stuckey, K. Krajewski, S. Jiang, P.P. Roller, and S. Wang Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins J. Med. Chem. 50 2007 1723 1726
12. M. Nguyen, R.C. Marcellus, A. Roulston, M. Watson, L. Serfass, S.R. Murthy Madiraju, D. Goulet, J. Viallet, L. Belec, X. Billot, S. Acoca, E. Purisima, A. Wiegmans, L. Cluse, R.W. Johnstone, P. Beauparlant, and G.C. Shore Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proc. Natl. Acad. Sci. U S A 104 2007 19512 19517
13. E. Rioux, X. Billot, K. Dairi, G. Gonzalez, J.-F. Lavallee, S. Tripathy, A. Babineau, S. Bailly, H. Chan, G. Chen, G. Gagnon, A. Jang, A. Khadir, R. Marcellus, D. Paquette, A. Roulston, B. St-Denis, N. Steenaart, M. Watson, Z. Zhang, D. Goulet, P. Beauparlant, G. Shore, and G. Attardo SAR study on aryl and heteroaryl bipyrrole inhibitors of Bcl antiapoptotic proteins with potent antitumor activity in vivo (IUPAC-ICOS-16 special issue) J. Mex. Chem. Soc. 50 2006 209
14. K. Daïri, Y. Yao, M. Faley, S. Tripathy, E. Rioux, X. Billot, D. Rabouin, G. Gonzalez, J.-F. Lavallee, and G. Attardo A scalable process for the synthesis of the Bcl inhibitor obatoclax Org. Process. Res. Dev. 11 2007 1051 1054
15. H. Tassidis, Z. Culig, A.G. Wingren, and P. Harkonen Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells Prostate 70 2010 1491 1500
16. Q. Zhang, H.Y. Wang, M. Marzec, P.N. Raghunath, T. Nagasawa, and M.A. Wasik STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes Proc. Natl. Acad. Sci. U S A 102 2005 6948 6953
17. H. Tassidis, L.J. Brokken, K. Jirstrom, R. Ehrnstrom, F. Ponten, D. Ulmert, A. Bjartell, P. Harkonen, and A.G. Wingren Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer Int. J. Cancer 126 2010 2296 2307
18. K.F. Chen, W.T. Tai, T.H. Liu, H.P. Huang, Y.C. Lin, C.W. Shiau, P.K. Li, P.J. Chen, and A.L. Cheng Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3 Clin. Cancer Res. 16 2010 5189 5199